Business Context and Reporting Period
This Form 8-K filing by DarioHealth Corp. (DRIO) reports corporate governance events occurring on March 1, 2020, with the report filed on March 5, 2020. The Company, incorporated in Delaware and headquartered in Israel, operates in the digital health sector.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on the appointment of new directors and associated compensation arrangements.
Material Changes
The primary material change is the expansion of the Board of Directors to fill existing vacancies:
- Yadin Shemmer: Appointed as a director. He brings experience as former CEO of Mango Health and President of the consumer business at Everyday Health.
- Adam Stern: Appointed as a director, nominated by Aegis Capital Corp. (the placement agent for the Company's November 2019 preferred stock offering). Mr. Stern previously served on the Company's board from 2011 to 2014.
Compensation and Governance Details
The filing details specific remuneration for the new directors:
- Yadin Shemmer:
- Annual board fee: $75,000 (in lieu of standard non-executive director fees).
- Stock Option: Granted an option to purchase 90,000 shares of common stock.
- Vesting Schedule: 15,000 shares vest at the six-month anniversary; the remaining 75,000 shares vest ratably over ten quarterly installments thereafter.
- Adam Stern:
- Compensation: Receives the same fees as other non-executive directors.
- Background: Head of Private Equity Banking at Aegis Capital Corp. and CEO of SternAegis Ventures.
- Historical Context: The appointment of Mr. Stern relates to the Company's preferred stock offering commencing November 27, 2019, where Aegis Capital Corp. received placement agent fees of $2,404,202 and warrants to purchase 719,243 shares at a weighted average exercise price of $4.31 per share.
Investor Verification Checklist
- Verify the vesting schedule and exercise price of the 90,000 stock options granted to Yadin Shemmer.
- Confirm the standard annual fee amount for non-executive directors to calculate Mr. Stern's total compensation.
- Review the Company's most recent 10-K or 10-Q for financial performance data, as this 8-K contains no financial results.
- Assess the strategic value of Mr. Shemmer's digital health operational experience and Mr. Stern's private equity and life science sector connections.